Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sachiko Miyake

Showing results (11-20 of 140) with videos related to

Pageof 14
Sort By:
Allergology International : Official Journal of the Japanese Society of Allergology|January 30, 2007
Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseasesShinji Oki, Sachiko Miyake
Methods in Molecular Biology (Clifton, N.J.)|April 8, 2014
Basic techniques for studies of iNKT cells and MAIT cellsAsako Chiba, Sachiko Miyake
Seikagaku. the Journal of Japanese Biochemical Society|May 22, 2007
[Immunomodulation by modified glycolipid ligand-stimulated invariant natural killer T (iNKT) cells]Shinji Oki, Sachiko Miyake
Journal of Neuroimmunology|August 6, 2018
Gut environmental factors and multiple sclerosisSachiko Miyake, Takashi Yamamura
Rinsho Shinkeigaku = Clinical Neurology|August 26, 2021
[Gut environment and multiple sclerosis]Sachiko Miyake, Daisuke Noto
Immunotherapy|May 31, 2012
B-cell-directed therapy: which B cells should be targeted and how?Takashi Yamamura, Sachiko Miyake
International Reviews of Immunology|April 25, 2007
Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseasesSachiko Miyake, Takashi Yamamura
Clinical Immunology (Orlando, Fla.)|March 15, 2020
Gut dysbiosis and multiple sclerosisDaisuke Noto, Sachiko Miyake
Current Medicinal Chemistry|October 16, 2008
Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapyManabu Araki, Sachiko Miyake, Takashi Yamamura
Modern Rheumatology|January 7, 2014
Potential of targeting natural killer T cells for the treatment of autoimmune diseasesSachiko Miyake, Asako Chiba, Takashi Yamamura
Pageof 14

Showing results (11-20 of 140) with videos related to

Sort By:
Pageof 14
Allergology International : Official Journal of the Japanese Society of Allergology|January 30, 2007
Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseasesShinji Oki, Sachiko Miyake
Methods in Molecular Biology (Clifton, N.J.)|April 8, 2014
Basic techniques for studies of iNKT cells and MAIT cellsAsako Chiba, Sachiko Miyake
Seikagaku. the Journal of Japanese Biochemical Society|May 22, 2007
[Immunomodulation by modified glycolipid ligand-stimulated invariant natural killer T (iNKT) cells]Shinji Oki, Sachiko Miyake
Journal of Neuroimmunology|August 6, 2018
Gut environmental factors and multiple sclerosisSachiko Miyake, Takashi Yamamura
Rinsho Shinkeigaku = Clinical Neurology|August 26, 2021
[Gut environment and multiple sclerosis]Sachiko Miyake, Daisuke Noto
Immunotherapy|May 31, 2012
B-cell-directed therapy: which B cells should be targeted and how?Takashi Yamamura, Sachiko Miyake
International Reviews of Immunology|April 25, 2007
Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseasesSachiko Miyake, Takashi Yamamura
Clinical Immunology (Orlando, Fla.)|March 15, 2020
Gut dysbiosis and multiple sclerosisDaisuke Noto, Sachiko Miyake
Current Medicinal Chemistry|October 16, 2008
Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapyManabu Araki, Sachiko Miyake, Takashi Yamamura
Modern Rheumatology|January 7, 2014
Potential of targeting natural killer T cells for the treatment of autoimmune diseasesSachiko Miyake, Asako Chiba, Takashi Yamamura
Pageof 14